Platelet adhesiveness

Platelet adhesiveness refers to the physiological capacity of blood platelets to adhere to the vascular subendothelial matrix or other biological surfaces, representing the initial and critical stage of thrombus formation [1, 10]. This property is a biological phenomenon rather than a single molecular target, and it is mediated by a sophisticated network of receptors such as the glycoprotein Ib-IX-V complex, glycoprotein VI (GPVI), and various integrins like alpha-IIb/beta-3 (GPIIb/IIIa) [10, 12]. In a healthy state, platelet adhesiveness ensures hemostasis by sealing vascular injuries; however, pathologically high adhesiveness is a primary driver of arterial thrombosis, leading to clinical events such as myocardial infarction and ischemic stroke [2, 14]. Pharmacological modulation of this property is the cornerstone of antithrombotic therapy, where drugs target specific signaling pathways or receptors—most notably P2Y12 and GPIIb/IIIa—to reduce the likelihood of clot formation in high-risk patients [4, 9, 16]. Understanding the molecular components of adhesiveness also provides insights into non-hemostatic roles, including inflammatory responses and the facilitation of cancer metastasis [1, 6].

Other names

Platelet adhesionPlatelet stickiness

Inhibition of specific molecular pathways that mediate platelet stickiness, including P2Y12 receptor antagonism, glycoprotein IIb/IIIa receptor blockade, cyclooxygenase-1 (COX-1) inhibition, and protease-activated receptor-1 (PAR-1) antagonism.